EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk

Hossaena Ayele iD, Jinhee Jo, Khurshida Begum, Chenlin Hu iD, Thanh M Le, M Jahangir Alam, Taryn A Eubank iD, Sigmund J Haidacher, Thomas D Horvath iD, Blake M Hanson iD, Kevin W Garey iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf512 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Hossaena Ayele und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Diseases, UTHealth Houston School of Public Health, University of Texas Health Science Center at Houston. Hauptthemen laut MEDLINE: Moxifloxacin, Vancomycin, Anti-Bacterial Agents, Clostridioides difficile. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Paratek Pharmaceuticals, Inc, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The epidemic Clostridioides difficile ribotype 027 (RT 027) strain is associated with bacterial virulence traits, including faster germination time and resistance to moxifloxacin, a second-generation fluoroquinolone. Although fluoroquinolones are linked to the RT 027 epidemic, studies to understand moxifloxacin as a high-risk antibiotic for C difficile infection (CDI) are limited. This study assessed the microbial taxonomic profile and metabolomic changes in healthy volunteers given moxifloxacin or oral vancomycin, an antibiotic known to increase CDI risk via gut perturbation.

Methods

This phase 1, nonblinded, randomized clinical trial comprised healthy volunteers aged 18 to 40 years who received moxifloxacin or vancomycin for 10 days. Stool samples were collected at baseline and 12 follow-up visits. Metataxonomics was completed by 16S rRNA sequencing and bile acid metabolites by liquid chromatography–tandem mass spectrometry.

Results

Moxifloxacin therapy caused minimal microbial disruption, although changes were observed in bacterial species from the Clostridiales order during therapy. Secondary bile acid concentrations decreased from day 0 to day 7 with moxifloxacin therapy. Vancomycin caused more significant changes in the microbiome, including increased Proteobacteria, decreased Clostridiales abundance, and a longer duration of decreased secondary bile acids.

Conclusions

Moxifloxacin use was associated with specific microbiome and metabolomic changes, increasing CDI risk albeit for a shorter period than vancomycin. This window of vulnerability may help to explain the risk of fluoroquinolones with the faster germination time for RT 027 strains. Clinical Trials Registration. ClinicalTrials.gov NCT06030219.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MoxifloxacinVancomycinAnti-Bacterial AgentsClostridioides difficileClostridium InfectionsFluoroquinolonesGastrointestinal MicrobiomeHumansAdultMaleFemaleYoung AdultAdolescentFecesAdministration, OralRNA, Ribosomal, 16SBile Acids and SaltsHealthy Volunteers

Stichwörter der Autor:innen

Clostridioides difficilefluoroquinolonesglycopeptideshuman subjectsmicrobiome

Substanzen

MoxifloxacinVancomycinAnti-Bacterial AgentsFluoroquinolonesRNA, Ribosomal, 16SBile Acids and Salts

Autor:innen und Institutionen

  • Center for Infectious Diseases, UTHealth Houston School of Public Health, University of Texas Health Science Center at Houston.
  • Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston.
  • Department of Pathology and Immunology, Baylor College of Medicine.
  • Department of Pathology, Texas Children's Hospital, Houston.

ORCID-Profile: Hossaena Ayele, Chenlin Hu, Taryn A Eubank, Thomas D Horvath, Blake M Hanson, Kevin W Garey

Förderung

  • Paratek Pharmaceuticals, Inc
  • National Institute of Allergy and Infectious Diseases, National Institutes of Health

Zitieren

APA

Ayele, H., Jo, J., Begum, K., Hu, C., Le, T. M., Alam, M. J., Eubank, T. A., Haidacher, S. J., Horvath, T. D., Hanson, B. M., & Garey, K. W. (2025). A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf512

Vancouver

Ayele H, Jo J, Begum K, Hu C, Le TM, Alam MJ, et al. A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf512

BibTeX
@article{Ayele2025,
  author = {Ayele, Hossaena and Jo, Jinhee and Begum, Khurshida and Hu, Chenlin and Le, Thanh M and Alam, M Jahangir and Eubank, Taryn A and Haidacher, Sigmund J and Horvath, Thomas D and Hanson, Blake M and Garey, Kevin W},
  title = {A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf512}
}
Kostenlos starten →